How Much Does Prolia (Denosumab) Cost in Maryland in 2026?

Prolia List Price and Maryland Retail Pricing

The wholesale acquisition cost (WAC) for Prolia remains approximately $1,500 per 60 mg prefilled syringe in 2026. Maryland retail pharmacies and provider offices mirror this national pricing, with the average cash-pay cost across the state holding at roughly $1,500 per injection [1]. Because Prolia is a physician-administered drug given as a subcutaneous injection every six months, annual out-of-pocket exposure for uninsured patients reaches $3,000.

Amgen has raised Prolia's list price incrementally since its 2010 FDA approval for postmenopausal osteoporosis. No interchangeable biosimilar has reached the U.S. market as of May 2026, though several denosumab biosimilar applications are under FDA review [2]. Until competition arrives, Maryland patients without insurance or manufacturer assistance face full WAC pricing.

Price variation exists between settings of care. Hospital outpatient infusion centers in the Baltimore-Washington corridor may bill a facility fee on top of drug cost, while independent rheumatology or endocrinology offices typically bill under Medicare Part B's buy-and-bill model with ASP + 6% reimbursement. Patients should request a site-of-service cost estimate before scheduling.

Maryland Medicaid Coverage for Denosumab

Maryland Medicaid covers Prolia (denosumab) for osteoporosis indications with prior authorization (PA). The PA process requires documentation that the patient meets one or more of the following criteria: a T-score of -2.5 or below on DXA scan, history of fragility fracture, or intolerance/contraindication to oral bisphosphonates such as alendronate [3].

The FREEDOM trial (N=7,868) demonstrated that denosumab 60 mg every 6 months reduced new vertebral fractures by 68% versus placebo over 36 months [4]. Maryland Medicaid's formulary committee references this evidence, along with the Endocrine Society's 2019 clinical practice guideline, when adjudicating PA requests. Approval rates are high when bisphosphonate failure or intolerance is documented.

For dual-eligible patients (Medicare + Medicaid), Prolia is typically billed through Medicare Part B as a physician-administered injectable. The Medicaid component covers remaining cost-sharing. Maryland's HealthChoice managed care organizations (MCOs), including Priority Partners, Jai Medical Systems, and CareFirst Community Health Plan, each process Prolia PAs through their own pharmacy benefit management systems [5].

Commercial Insurance Coverage in Maryland

Most commercial plans sold on the Maryland Health Benefit Exchange and employer-sponsored plans cover Prolia under the medical benefit rather than the pharmacy benefit, since it requires in-office administration [6]. Typical patient responsibility after deductible ranges from 20% to 40% coinsurance, translating to $300-$600 per injection without additional assistance.

CareFirst BlueCross BlueShield, the state's largest insurer, lists denosumab on its specialty tier with step therapy requiring trial of at least one oral bisphosphonate. Kaiser Permanente Mid-Atlantic and UnitedHealthcare plans in Maryland follow similar utilization management protocols aligned with the American Association of Clinical Endocrinology (AACE) guidelines.

The 2020 AACE/ACE guideline recommends denosumab as a first-line option for patients at very high fracture risk (recent fracture within 12 months, T-score below -3.0, or multiple vertebral fractures) [7]. Maryland insurers increasingly approve initial denosumab without step therapy for patients meeting these very-high-risk criteria, per the FRAX fracture risk assessment tool thresholds validated in FREEDOM trial populations.

The Amgen Assist Savings Card in Maryland

Amgen's patient assistance program offers two tiers relevant to Maryland residents. The Amgen Assist copay card reduces out-of-pocket costs for commercially insured patients to as low as $0 per dose, with a maximum annual benefit that varies by plan year. Eligibility requires commercial insurance (not Medicare, Medicaid, or other government programs).

For uninsured or underinsured Maryland patients, the Amgen Safety Net Foundation provides Prolia at no cost to qualifying households earning below 400% of the federal poverty level [8]. Application requires income documentation and a valid prescription. Processing typically takes 2-4 weeks.

A key consideration: patients who start Prolia must continue treatment or transition to an alternative antiresorptive. The FREEDOM extension study showed that discontinuation of denosumab leads to rapid bone mineral density loss and rebound vertebral fractures within 12-18 months [9]. Before enrolling in manufacturer assistance, Maryland patients should confirm they can maintain access long-term or have a documented transition plan to zoledronic acid.

Compounded Denosumab in Maryland: Legality and Access

Compounded denosumab is available in Maryland through licensed 503A compounding pharmacies operating under state Board of Pharmacy oversight [10]. Maryland follows the federal framework established by the Drug Quality and Security Act (DQSA) of 2013, which permits 503A pharmacies to compound copies of commercially available drugs when a prescriber documents a clinical difference for an individual patient (such as dose adjustment or preservative sensitivity).

Maryland's Board of Pharmacy requires 503A facilities to maintain patient-specific prescriptions, comply with USP 797 sterile compounding standards, and undergo routine inspections [11]. Patients considering compounded denosumab should verify the pharmacy holds a current Maryland Board of Pharmacy sterile compounding permit.

Cost for compounded denosumab through 503A pharmacies may differ substantially from branded Prolia. However, compounded biologics carry considerations around potency verification and stability testing that differ from FDA-approved products. The FDA's 2023 guidance on compounding biological products outlines the regulatory boundaries. Maryland patients should discuss with their prescriber whether a compounded preparation meets clinical needs for their specific fracture risk profile.

Telehealth Prescribing of Prolia in Maryland

Maryland permits telehealth prescribing of Prolia under the Maryland Telehealth Act, which was expanded during 2020-2021 and made permanent through subsequent legislation. A physician or qualified provider can evaluate a patient via synchronous video, review DXA results and laboratory values, and issue a prescription for denosumab without an in-person visit [12].

The practical workflow: a Maryland-licensed clinician conducts a telehealth osteoporosis consultation, orders or reviews a DXA scan and relevant labs (calcium, 25-hydroxyvitamin D, renal function), then prescribes Prolia. The injection itself requires an in-person visit at a clinic, infusion center, or home health setting. Some Maryland practices now offer combined telehealth consultation with a separate injection-only appointment, reducing total visit burden for patients in rural counties like Garrett, Allegany, or Somerset [13].

Medicare telehealth flexibilities under the Consolidated Appropriations Act continue through 2026, meaning Maryland Medicare beneficiaries can access osteoporosis management via telehealth regardless of geographic location.

Medicare Part B Coverage for Maryland Residents

For Maryland's Medicare population, Prolia falls under Part B as a physician-administered drug. Medicare reimburses at ASP + 6%, and the patient owes 20% coinsurance after the Part B deductible ($257 in 2026) [14]. That translates to approximately $280-$320 per injection out-of-pocket for a standard Medicare beneficiary without supplemental coverage.

Medigap plans (Plans C, F, and G are most common in Maryland) cover the 20% coinsurance in full, reducing patient cost to zero after the annual Part B deductible [15]. Medicare Advantage plans in Maryland (CareFirst Advantage, Kaiser Senior Advantage, Aetna Medicare) may require prior authorization but generally cover Prolia with specialist copays ranging from $0 to $50 depending on plan tier.

The National Osteoporosis Foundation estimates that 10.2 million Americans have osteoporosis and 43.4 million have low bone mass. Maryland's aging population, particularly in retirement-heavy counties like Talbot, Worcester, and Queen Anne's, represents a substantial Medicare beneficiary pool for denosumab treatment. Timely fracture risk assessment using FRAX and DXA, as recommended by the USPSTF, can identify candidates before first fracture [16].

Cost Comparison: Prolia vs. Alternative Osteoporosis Therapies in Maryland

Understanding relative costs helps Maryland patients and prescribers make informed formulary decisions. Generic alendronate (Fosamax) costs $4-$15 per month at Maryland pharmacies. Zoledronic acid (Reclast), given as an annual IV infusion, carries a list price of approximately $1,200 per infusion but is available generically for $300-$500 through hospital outpatient settings [17].

Anabolic agents represent the highest-cost tier. Teriparatide (Forteo) lists at approximately $3,600 per month, while romosozumab (Evenity) costs roughly $1,825 per monthly injection for 12 months [18]. The VERO trial showed teriparatide superior to risedronate for vertebral fracture reduction, while the ARCH trial demonstrated romosozumab followed by alendronate reduced fracture risk versus alendronate alone.

For Maryland patients with very high fracture risk, the Endocrine Society recommends initial anabolic therapy followed by transition to an antiresorptive like denosumab or zoledronic acid [19]. This sequencing approach may affect total cost calculations over a 3-5 year treatment horizon.

| Therapy | Route | Frequency | Approximate Annual Cost (MD) | |---------|-------|-----------|------------------------------| | Alendronate (generic) | Oral | Weekly | $50-$180 | | Zoledronic acid (generic) | IV | Annually | $300-$500 | | Prolia (denosumab) | SC | Every 6 months | $3,000 | | Forteo (teriparatide) | SC | Daily x 24 months | $43,200 | | Evenity (romosozumab) | SC | Monthly x 12 months | $21,900 |

Reducing Your Out-of-Pocket Cost: A Step-by-Step Approach

Maryland patients can systematically reduce Prolia costs through a layered strategy. First, confirm insurance coverage tier and prior authorization requirements by calling the number on the back of the insurance card. Second, apply for the Amgen Assist copay card if commercially insured, or the Safety Net Foundation if uninsured [20]. Third, ask the prescribing office about site-of-service optimization. An injection at an independent physician office versus a hospital outpatient department can save $200-$400 in facility fees alone.

For patients denied coverage, Maryland's Insurance Administration accepts external review appeals. The denial must reference the specific clinical indication and supporting evidence, including DXA T-score, FRAX 10-year probability, prior therapy attempts, and relevant comorbidities [21]. Maryland law requires insurers to respond to external review within 45 days for non-urgent cases.

Patients approaching the Medicare Part D coverage gap ("donut hole") should note that Prolia is billed under Part B, not Part D, and therefore does not contribute to Part D true out-of-pocket costs. This distinction matters for Maryland beneficiaries managing multiple specialty medications across both benefit categories.